Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1214341-16-8

Post Buying Request

1214341-16-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1214341-16-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1214341-16-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,4,3,4 and 1 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1214341-16:
(9*1)+(8*2)+(7*1)+(6*4)+(5*3)+(4*4)+(3*1)+(2*1)+(1*6)=98
98 % 10 = 8
So 1214341-16-8 is a valid CAS Registry Number.

1214341-16-8Relevant articles and documents

Surprisingly High Selectivity and High Affinity in Mercury Recognition by H-Bonded Cavity-Containing Aromatic Foldarands

Shen, Jie,Ren, Changliang,Zeng, Huaqiang

, p. 5387 - 5396 (2017)

In the absence of macrocyclic ring constraints, few synthetic systems, possessing a mostly solvent-independent well-folded conformation that is predisposed for highly selective and high affinity recognition of metal ions, have been demonstrated. We report here such a unique class of conformationally robust modularly tunable folding molecules termed foldarands that can recognize Hg2+ ions surprisingly well over 22 other metal ions. Despite the lack of sulfur atoms and having only oxygen-donor atoms in its structure, the best foldarand molecule, i.e., tetramer 4, exhibits a selectivity factor of at least 19 in differentiating the most tightly bound Hg2+ ion from all other metal ions, and a binding capacity that is ≥18 times that of thio-crown ethers. These two noteworthy binding characters make possible low level removal of Hg2+ ions. With a [4]:[Hg2+] molar ratio of 5:1 and a single biphasic solvent extraction, the concentration of Hg2+ ions could be reduced drastically by 98% (from 200 to 4 ppb) in pure water. 4 could also effect a highly efficient reduction in mercury content by 98% (from 500 to 10 ppb) in artificial groundwater via multiple successive extractions with an overall consumption of 4 being 9:1 in terms of [4]:[Hg2+] molar ratio.

Amide compound as well as preparation method and application thereof

-

Paragraph 0155-0159; 0195-0199, (2021/04/17)

The invention provides an amide compound as well as a preparation method and application thereof. The amide compound has a structure as shown in a formula I in the specification. The amide compound disclosed by the invention can have high insecticidal act

Novel pyrimidine sulfonamide derivatives and a mite controlling composition comprising thereof

-

Paragraph 0048-0057, (2021/06/01)

The present invention relates to a novel amide derivative and a composition for controlling an acaricide comprising the same. By introducing a heterocyclic substituent into the amide derivative, a composition for controlling an acaricide activity can be p

Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)

Babu, Yarlagadda S,Chambers-Wilson, Ramanda,Chen, Xilin,Chintareddy, Venkat,Davis Parker, Cynthia,Juarez, Luis,Kellogg-Yelder, Debra,Kotian, Pravin L,Lu, Pengcheng,Muppa, Saritha,Polach, Kevin J,Raman, Krishnan,Vadlakonda, Satish,Williams, Jason,Wu, Minwan,Zhang, Weihe

supporting information, p. 12453 - 12468 (2021/09/13)

Hereditary angioedema (HAE) is a rare and potentially life-threatening disease that affects an estimated 1 in 50000 individuals worldwide. Until recently, prophylactic HAE treatment options were limited to injectables, a burdensome administration route that has driven the need for an oral treatment. A substantial body of evidence has shown that potent and selective plasma kallikrein inhibitors that block the generation of bradykinin represent a promising approach for the treatment of HAE. Berotralstat (BCX7353, discovered by BioCryst Pharmaceuticals using a structure-guided drug design strategy) is a synthetic plasma kallikrein inhibitor that is potent and highly selective over other structurally related serine proteases. This once-daily, small-molecule drug is the first orally bioavailable prophylactic treatment for HAE attacks, having successfully completed a Phase III clinical trial (meeting its primary end point) and recently receiving the U.S. Food and Drug Administration's approval for the prophylactic treatment of HAE attacks in patients 12 years and older.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1214341-16-8